Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive weekly Ambisome in ICU patients with multiple Candida colonization and sepsis
2007-004444-71Phase 4Active
- Sponsor
- Fovea Pharmaceuticals
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amphotericin b in invasive candidiasis, sponsored by Fovea Pharmaceuticals. Primary endpoints: Product tolerability and Safety of Ambisome weekly administration. Started Sep 2007; status: active.
02
Drugs
amphotericin b
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on 2007-004444-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004444-71.